Back
Cyclo Therapeutics Quote, Financials, Valuation and Earnings
The dark truth about AI
Click here to learn more...
Sell
31
CYTH
Cyclo Therapeutics
Last Price:
0.59
Seasonality Move:
18.97%
7 Day Trial
ALL ACCESS PASS
$
7
Zero Day Options Trade LIVE Tuesday at 2 p.m. ET!
Discover The Zero Day Loophole (BEFORE Tues at 2 p.m. ET!)Cyclo Therapeutics Price Quote
$0.59
+0.01 (+-0.84%)
(Updated: December 14, 2024 at 5:29 AM ET)
Cyclo Therapeutics Key Stats
Sell
31
Cyclo Therapeutics (CYTH)
is a Sell
Day range:
$0.57 - $0.61
52-week range:
$0.57 - $2.12
Dividend yield:
0%
P/E ratio:
0.00
P/S ratio:
18.00
P/B ratio:
0%
Volume:
29.5K
Avg. volume:
25.8K
1-year change:
-51.27%
Market cap:
$16.7M
Revenue:
$1.1M
EPS:
$-0.9
How Much Does Cyclo Therapeutics Make?
-
How Much Are Cyclo Therapeutics's Sales Annually?
CYTH Revenues are $1.1M -
How Much Profit Does Cyclo Therapeutics's Make A Year?
CYTH net income is -$20.1M
Is Cyclo Therapeutics Growing As A Company?
-
What Is Cyclo Therapeutics's Growth Rate Quarterly?
Quarterly YoY revenue growth is -0.53% -
What Is Cyclo Therapeutics's EPS Quarterly YoY Growth Rate?
Quarterly, year-over-year diluted EPS growth rate is 0%
Cyclo Therapeutics Stock Price Performance
-
Did Cyclo Therapeutics Stock Go Up Last Month?
Cyclo Therapeutics share price went down by -19.46% last month -
Did CYTH's Share Price Rise Over The Last Year?
CYTH share price fell by -51.27% over the past 1 year
What Is Cyclo Therapeutics 52-Week High & Low?
-
What Is Cyclo Therapeutics’s 52-Week High Share Price?
Cyclo Therapeutics has traded as high as $2.12 over the past 52 weeks -
What Is Cyclo Therapeutics’s 52-Week Low Share Price?
Cyclo Therapeutics has traded as low as $0.57 over the past 52 weeks
Cyclo Therapeutics Price To Free Cash Flow
Data Unavailable
Is It Risky To Buy Cyclo Therapeutics?
-
How Much Debt Does Cyclo Therapeutics Have?
Total long term debt quarterly is $12.2M -
How Much Cash Does Cyclo Therapeutics Have?
Cash and short term investments quarterly total is $928K -
What Is Cyclo Therapeutics’s Book Value Per Share?
Book value per share is -0.47
Is Cyclo Therapeutics Cash Flow Positive?
-
What Is CYTH Cash Flow From Operations?
Cash flow from operations (TTM) is -$22.5M -
What Is Cyclo Therapeutics’s Cash Flow From Financing?
Cash flow from financing (TTM) is $21.6M -
What Is Cyclo Therapeutics’s Cash Flow From Investing?
Cash flow from investing (TTM) is $0
Cyclo Therapeutics Return On Invested Capital
-
Is Management Doing A Good Job?
CYTH return on invested capital is -20419.22% -
What Is Cyclo Therapeutics Return On Assets?
ROA measures how assets are converting to revenues and is -344.63% -
What Is CYTH Return On Equity?
ROE is a measure of profitability and is 0%
Cyclo Therapeutics Earnings Date & Stock Price
-
What Is Cyclo Therapeutics's Stock Price Today?
A single share of CYTH can be purchased today for 0.58 -
What Is Cyclo Therapeutics’s Stock Symbol?
Cyclo Therapeutics trades on the nasdaq under the ticker symbol: CYTH -
When Is Cyclo Therapeutics’s Next Earnings Date?
The next quarterly earnings date for Cyclo Therapeutics is scheduled on March 18, 2025 -
When Is CYTH's next ex-dividend date?
Cyclo Therapeutics's next ex-dividend date is December 15, 2024 -
How To Buy Cyclo Therapeutics Stock?
You can buy Cyclo Therapeutics shares by opening an account at a top tier brokerage firm, such as TD Ameritrade or tastyworks.
Cyclo Therapeutics Competitors
-
Who Are Cyclo Therapeutics's Competitors?
Below is a list of companies who compete with Cyclo Therapeutics or are related in some way:
Cyclo Therapeutics Dividend Yield
-
What Is CYTH Dividend Yield?
Cyclo Therapeutics’s dividend yield currently is 0% -
What Is Cyclo Therapeutics’s Payout Ratio?
Cyclo Therapeutics’s payout ratio is 0% -
When Did Cyclo Therapeutics Last Pay A Dividend?
The latest dividend pay date is December 15, 2024 -
What Is Cyclo Therapeutics’s Dividend Per Share?
Cyclo Therapeutics pays a dividend of $0.00 per share
Cyclo Therapeutics Analyst Estimates
| YoY Growth | Past Surprise | |
|---|---|---|
| EPS: | 0% | 0% |
| Revenue: | -52.82% | -20.49% |
Analyst Recommendations
| Buy Recommendations: | 1 |
|---|---|
| Hold Recommendations: | 2 |
| Sell Recommendations: | 0 |
| Price Target: | 0.95 |
| Upside from Last Price: | 63.82% |